Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.

14 Nov 2011

Intensive therapy can preserve kidney function in patients with type 1 diabetes

People with type 1 diabetes are at high risk of developing kidney disease, but no therapies are proven to prevent impaired kidney function in these patients. In the Diabetes Control and Complications Trial (DCCT), Ian de Boer, MD and his team looked to see if intensive diabetes therapy aimed at reducing blood sugar as close to the normal range as possible might protect type 1 diabetics' kidney function. The study's results were presented during the American Society of Nephrology's Annual Kidney Week.

14 Nov 2011

Maintaining normal blood glucose levels prevents long-term kidney complications

Maintaining good glucose control early in the course of type 1 diabetes could lessen the long-term risk of kidney disease, as measured by a common test of kidney function.

14 Nov 2011

New information on kidney-related policies in the U.S.

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on kidney-related policies in the United States.

14 Nov 2011

NIDDK-funded study to develop approaches for chronic kidney disease management

Cleveland Clinic nephrologist Joseph Nally Jr., M.D., has been awarded a three-year, $720,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study and develop approaches for disease management for patients with chronic kidney disease.

14 Nov 2011

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease.

14 Nov 2011

Salt – is it bad for the heart? Debate continues

Salt or high sodium intake in diet has drawn attention of researchers for a while now. The U.S. Food and Drug Administration held a day-long hearing today, discussing strategies to help Americans cut the salt from their diets as a latest attempt to curb sodium in the American diet.

13 Nov 2011

Updates on dietary benefits and dangers in kidney disease patients

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on dietary benefits and dangers in kidney disease patients.

11 Nov 2011

Pediatric racial minorities less likely to get kidney transplants

Among children with kidney disease, certain races are less likely to get kidney transplants and are more likely to die than other races, according to two studies from Emory University that were presented during the American Society of Nephrology's Annual Kidney Week.

11 Nov 2011

Aristolochic acid leads to kidney failure, upper urinary tract cancer

Aristolochic acid, a component of a plant used in herbal remedies since ancient times and still used in certain herbal medicines worldwide, leads to kidney failure and upper urinary tract cancer in individuals exposed to the toxin.

10 Nov 2011

GHSU expert to again coordinate two national diabetes initiatives

Two national efforts supporting diabetes research will again be coordinated by a Georgia Health Sciences University bioinformatics expert.

10 Nov 2011

Insulin resistance associated with cortical atrophy and brain dysfunction

Many complications of diabetes, including kidney disease, foot problems and vision problems are generally well recognized. But the disease's impact on the brain is often overlooked.

9 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

HeRO graft device provides long-term AV access for hemodialysis patients

University Hospitals Case Medical Center physicians are utilizing a novel approach to solve a long standing problem for chronic kidney disease patients on hemodialysis.

5 Nov 2011

Arginase-2 enzyme plays a major role in diabetic nephropathy

The enzyme arginase-2 plays a major role in kidney failure, and blocking the action of this enzyme might lead to protection against renal disease in diabetes, according to researchers.

5 Nov 2011

VA announces 13 new awards in 2010 Industry Innovation Competition

The Department of Veterans Affairs today announced 13 new awards in the agency's 2010 Industry Innovation Competition. The new projects will give VA an opportunity to evaluate new ways to enhance care and benefits for Veterans.

5 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

JDC receives NIDDK grant for research into diabetic retinopathy, kidney disease

Joslin Diabetes Center has received a $3.9 million DP3 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to identify protective factors that enable many Joslin 50-Year Medalists to remain free of commonly occurring diabetes complications.

3 Nov 2011